(19)
(11) EP 3 143 047 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.09.2022 Bulletin 2022/36

(45) Mention of the grant of the patent:
20.07.2022 Bulletin 2022/29

(21) Application number: 15724070.6

(22) Date of filing: 15.05.2015
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
 A61K 39/395(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2875; C07K 16/244; A61P 13/12; A61P 17/00; A61P 17/02; A61P 19/02; A61P 21/00; A61P 21/04; A61P 25/00; A61P 29/00; A61P 3/00; A61P 35/00; A61P 37/00; A61P 37/02; A61P 37/08; A61P 7/00; A61P 7/04; A61P 9/00
(86) International application number:
PCT/IB2015/053602
(87) International publication number:
WO 2015/173782 (19.11.2015 Gazette 2015/46)

(54)

BELIMUMAB FORMULATION

BELIMUMAB FORMULIERUNG

FORMULATION DE BELIMUMAB

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.05.2014 US 201461994427 P
18.12.2014 US 201462093734 P
22.12.2014 US 201462095181 P

(43) Date of publication of application:
22.03.2017 Bulletin 2017/12

(60) Divisional application:
19185861.2 / 3715371
20150351.3 / 3719038

(73) Proprietors:
  • GlaxoSmithKline Intellectual Property Management Limited
    Brentford, Middlesex TW8 9GS (GB)
  • GlaxoSmithKline Intellectual Property Limited
    Brentford, Misslesex TW8 9GS (GB)

(72) Inventors:
  • BLAKE-HASKINS, Angela
    Gaithersburg, Maryland 20878 (US)
  • MARSHALL, Tristan
    Rockville, Maryland 20850 (US)
  • O'BERRY, Kristen
    Gaithersburg, Maryland 20878 (US)
  • PERKINS, Melissa D.
    McPherson, Kansas 67460 (US)

(74) Representative: Lee, Alison Lesley et al
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2014/114651
WO-A2-03/039485
WO-A2-2012/076670
 WO-A2-03/016468
WO-A2-2006/083689
   
  • April ET AL: "product monograph BENLYSTA TM", , 16 April 2014 (2014-04-16), XP055203701, Retrieved from the Internet: URL:http://www.gsk.ca/english/docs-pdf/pro duct-monographs/Benlysta.pdf [retrieved on 2015-07-21]
  • WANG W ET AL: "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 96, no. 1, 1 January 2007 (2007-01-01), pages 1-26, XP009084505, ISSN: 0022-3549, DOI: 10.1002/JPS.20727
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).